Company profile for Intercept Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-...
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
10 Hudson Yards, 37th Floor, New York, NY 10001
Telephone
Telephone
+646-747-1000
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.reuters.com/business/healthcare-pharmaceuticals/intercept-pharma-pulls-liver-disease-drug-us-after-regulators-request-2025-09-11/

REUTERS
12 Sep 2025

https://www.globenewswire.com/news-release/2025/09/11/3148535/23024/en/Intercept-Announces-Voluntary-Withdrawal-of-OCALIVA-for-Primary-Biliary-Cholangitis-PBC-from-the-US-Market-US-Clinical-Trials-Involving-Obeticholic-Acid-Placed-on-Clinical-Hold.html

GLOBENEWSWIRE
11 Sep 2025

https://www.prnewswire.com/news-releases/cristcot-appoints-richard-kim-as-chief-commercial-officer-302476944.html

PR NEWSWIRE
10 Jun 2025

https://www.globenewswire.com/news-release/2025/04/30/3071287/23024/en/Intercept-Announces-Data-to-be-Presented-at-Digestive-Disease-Week-2025.html

GLOBENEWSWIRE
30 Apr 2025

https://www.fiercepharma.com/pharma/ipsens-liver-disease-drug-iqirvo-promising-launch-battle-gileads-livdelzi

FIERCE PHARMA
17 Apr 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/vraylar-sales-growth-seen-slowing-2025-says-richter-ceo-2024-12-12/

REUTERS
12 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty